Lilly Forteo
Executive Summary
FDA Endocrinologic & Metabolic Drugs Advisory Committee will review teriparatide (NDA 21-318) July 27 for the treatment of osteoporosis in post-menopausal women and in men (1"The Pink Sheet" May 14, In Brief). The committee will meet at 8 a.m. at the Holiday Inn in Bethesda, Md
You may also be interested in...
Lilly Forteo
FDA Endocrinologic & Metabolic Drugs Advisory Committee will review osteoporosis drug teriparatide this summer, Lilly tells Deutsche Bank Alex Brown 2001 healthcare conference May 9 in Baltimore. The committee is tentatively scheduled to meet July 26-27. Forteo Phase III trial results were published in The New England Journal of Medicine May 10. The publication could have coincided with approval of the drug if it had received a priority review; FDA, however, designated it as a standard NDA
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials